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Abstract
Increasing evidence suggests that chromosomal regions containing microRNAs are functionally important in cancers. Here,
we show that genomic loci encoding miR-204 are frequently lost in multiple cancers, including ovarian cancers, pediatric
renal tumors, and breast cancers. MiR-204 shows drastically reduced expression in several cancers and acts as a potent
tumor suppressor, inhibiting tumor metastasis in vivo when systemically delivered. We demonstrated that miR-204 exerts
its function by targeting genes involved in tumorigenesis including brain-derived neurotrophic factor (BDNF), a neurotrophin
family member which is known to promote tumor angiogenesis and invasiveness. Analysis of primary tumors shows that
increased expression of BDNF or its receptor tropomyosin-related kinase B (TrkB) parallel a markedly reduced expression of
miR-204. Our results reveal that loss of miR-204 results in BDNF overexpression and subsequent activation of the small
GTPase Rac1 and actin reorganization through the AKT/mTOR signaling pathway leading to cancer cell migration and
invasion. These results suggest that microdeletion of genomic loci containing miR-204 is directly linked with the
deregulation of key oncogenic pathways that provide crucial stimulus for tumor growth and metastasis. Our findings
provide a strong rationale for manipulating miR-204 levels therapeutically to suppress tumor metastasis.
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Introduction
Identification of chromosomal regions harboring oncogenes and
tumor suppressor is crucial for understanding of the tumor
pathogenesis and improved treatment outcomes [1]. Although
several cancer-related genes have been identified in regions with
chromosomal abnormalities [2], additional regions with random
or recurrent chromosomal abnormalities harboring factors
important in cancer growth and progression remain to be
identified. Recent studies indicate that microRNAs (miRNAs)
are one such group of factors [3]. MiRNAs are small, endogenous,
non-coding RNAs that regulate post-transcriptional gene expres-
sion by binding to 39 untranslated regions (UTRs) of target
mRNAs. MiRNAs are known to play crucial functions in multiple
biological processes including development and differentiation [4],
and deregulated expression of miRNAs has been implicated in
several human diseases including cancer [5]. Growing evidence
suggests that miRNAs can act as oncogenes or tumor suppressor
genes [6].
In this study, we focused on chromosomal loci containing miR-
204. MiR-204 has been reported to play important roles in smooth
muscle cell calcification as well as endoplasmic reticulum stress
response in trabecular meshwork cells [7,8]. In addition, recent
reports have shown equally important roles for miR-204 in
tumorigenesis, including regulation of carcinogenesis in peripheral
nerve sheath tumors, and migration and invasion of endometrial
cancer cell lines [9,10]. However, very little is known about the
mechanism by which miR-204 regulates oncogenesis in general,
and tumor growth and metastasis in breast and ovarian cancers in
particular. Furthermore, virtually nothing is known about whether
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miR-204 can be targeted therapeutically and how miR-204
expression is regulated in cancers. Our results reveal that
chromosomal loci containing miR-204 is frequently lost, resulting
in its lower expression in multiple cancers. We demonstrate that
miR-204 acts as a potent tumor growth and metastasis suppressor.
Importantly, our results show that miR-204 can be targeted
therapeutically as systemic delivery of miR-204 inhibited breast
cancer lung metastasis without causing any hepatotoxicity. We
found that miR-204 acts as a tumor suppressor by targeting the
function of genes associated with tumorigenesis, including brain-
derived neurotrophic factor (BDNF). BDNF is a physiologically
important nerve growth factor that plays a critical role in the
development of nervous system by binding and subsequently
activating the tyrosine kinase receptor, tropomyosin-related kinase
B (TrkB) [11,12]. In addition, the BDNF/TrkB pathway is
reported to have a critical role in tumorigenesis as it promotes
proliferation, differentiation, angiogenesis and tumor invasiveness
[13]. Overexpression of BDNF/TrkB has also been implicated in
poor prognosis of several solid tumors including neuroblastoma,
ovarian, breast, prostate and lung cancers [14,15,16]. Our findings
reveal that loss of miR-204 results in BDNF/TrkB overexpression
and concomitant activation of the AKT/mTOR/Rac1 signaling
pathway, leading to actin reorganization during cancer cell
migration and invasion. These results underline the functional
importance of chromosomal regions containing specific miRNAs
in tumor growth and metastasis.
Results
Somatic Loss of miR-204 in Cancers
To identify miRNAs that are associated with aberrant
chromosomal regions in human cancers, we used high-resolution
custom miRNA comparative genomic hybridization (CGH) and
high-density CGH public domain datasets for ovarian cancers,
breast cancers and pediatric renal tumors. This analysis revealed
several miRNAs in the minimal chromosomal deletion and
amplification regions of these tumors. To begin to understand
the functional importance of chromosomal loci associated with
miRNAs in tumorigenesis, we initially focused on miRNAs
exhibiting genomic loss (Figure S1A). The 9q21.12 chromosomal
region containing miR-204 was frequently lost in 44.63% (158/
354) of ovarian cancers, 28% (10/35) of breast cancers and 40%
(15/38) of pediatric renal tumors (Figure 1A, 1B, and Figure S1B),
which is further verified by quantitative genomic real-time PCR
analysis (Figure 1C and 1D). Furthermore, reduction in the levels
of mature miR-204 also strongly correlated with its genomic DNA
content in all three tumor types (Figure 1E–1G).
MiR-204 Acts as a Potent Tumor Growth and Metastasis
Suppressor
The drastically reduced expression of miR-204 in multiple
cancer tissues prompted us to address the role of miR-204 in
tumorigenesis. To determine this, we first assessed the effect of
miR-204 on anchorage independent growth. Embryonal kidney
HEK-293 cells (HEK-293 cells passaged over 52 times are
reported to be highly tumorigenic [17]) overexpressing miR-204
exhibited reduced colony-forming capacity, which was rescued
with the overexpression of an inhibitor of miR-204 (Figure 2A).
Similar results were also obtained with miR-204 overexpressing
breast cancer MDA-MB-231 and ovarian cancer SKOV3 cells
(data not shown). To further confirm miR-204’s potential tumor
suppressor-like activity, high-passage HEK-293 cells stably over-
expressing either miR-204 or a scrambled sequence were injected
into the kidney capsules of nude mice and tumor growth and
metastasis were evaluated 24 days after injection. In sharp contrast
to control tumors, miR-204 overexpressing tumors were dramat-
ically reduced in size (Figure 2B). Next, we examined whether
miR-204 also inhibits tumor cell invasion. Histological analysis of
xenograft tumor sections indicated drastically decreased or no
invasiveness of tumors into renal tissues that overexpressed miR-
204 compared to control (Figure 2C). Consistent with this, miR-
204 overexpression drastically reduced the migratory and invasive
capabilities of breast cancer (MDA-MB-231) and ovarian cancer
(SKOV3) cells (Figure 2D and data not shown) in vitro.
Therapeutic Targeting of miR-204
To further substantiate the metastasis suppressor activity of
miR-204 we performed therapeutic experiments in the breast
cancer lung metastasis model. We first established lung metastases
by tail vein injection of MDA-MB-231 breast cancer cells
expressing luciferase-GFP, and subsequently injected miR-204 or
miR-204 mutant oligo (negative control) into the tail vein of nude
mice every 5 days for 30 days using LANCErII, a lipid-based
in vivo delivery vehicle. Interestingly, systemic delivery of miR-
204 resulted in significant reduction or elimination of lung
metastases, while miR-204 mutant oligo injected mice had severe
lung metastasis, as measured over the 60-day period (Figure 3A–
3D and Figure S2). Importantly, mice injected with miR-204
showed no obvious side effects as revealed by absence of
hepatotoxicity or changes in body weight (Figure 3E and data
not shown). These results indicate that miR-204 can be a safe and
viable therapeutic regimen to treat tumor growth and metastasis.
MiR-204 Targets Genes Associated with Tumorigenesis
To understand the mechanism by which miR-204 may play a
role in tumorigenesis, we identified genes regulated by miR-204.
Since most miRNAs act to decrease target mRNA levels [18], we
performed gene expression analyses on cells overexpressing miR-
204 and determined the potential targets of miR-204. Of the genes
altered in miR-204 overexpressing cells, downregulated genes are
most likely to be directly targeted by miR-204. Interestingly,
several of the downregulated genes are associated with cancer-
related processes and physically or functionally interact with each
other, as revealed by pathway-based analyses (Figure S3). We
performed detailed analyses on two such genes: BDNF and Ezrin
that showed higher levels of alteration in our microarray analysis
and featured in all predicted biological pathways with highest
functional enrichment significance. BDNF with its receptor TrkB
is known play a critical role in tumor angiogenesis and metastasis;
and Ezrin, a cytoskeletal organizer protein, has been implicated in
the tumor growth metastasis of several adult and pediatric tumors
including osteosarcoma, mammary and pancreatic adenocarcino-
mas, ovarian carcinoma as well as rhabdomyosarcoma and
pediatric renal tumors [19,20,21]. Moreover, multiple target
prediction algorithms, including SvMicrO [22], Bayesian decision
fusion approach [23], and miRmate [24] that we have recently
generated as well as TargetScan [25] and Pictar [26], also
predicted BDNF and Ezrin to be targeted by miR-204. Further-
more, miR-204 binding sites were found to be evolutionarily
conserved throughout vertebrates, suggesting it to have an
important regulatory function across a variety of species.
Importantly, miR-204 and BDNF/TrkB as well Ezrin expression
showed a strong inverse correlation in several tumors (Figure 4A–
4C and Figure S4A–S4C).
To validate our microarray and target prediction results, we first
examined whether miR-204 targets BDNF/Ezrin by binding to the
predicted site in its 39 UTR (Figure 4D and Figure S4D). Indeed,
the luciferase activity of a pMIR-reporter construct containing the
Chromosomal Loss of miR-204
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BDNF or Ezrin 39 UTR was significantly repressed, which was
further reduced in cells overexpressing miR-204 when compared
to construct without the 39 UTR (Figure 4E and Figure S4D). In
contrast, mutation of the seed sequence in BDNF 39 UTR-
containing construct not only restored luciferase activity to near
that of the wild-type construct but also rendered transcripts from
these constructs insensitive to miR-204 overexpression (Figure 4E),
confirming a specific interaction between miR-204 and the
predicted binding site in the 39 UTRs of these genes. To further
substantiate these results, we determined the levels of BDNF/
Ezrin in cells overexpressing miR-204. MiR-204 overexpression
resulted in significant reduction of BDNF/Ezrin both at the RNA
and protein levels (Figure 4F–4H and Figure S4E and S4F). Next,
we examined whether or not BDNF and Ezrin are functionally
important targets of miR-204. To address that we performed
rescue experiments. Reintroduction of BDNF or Ezrin rescued
miR-204 induced phenotypes including anchorage-independent
growth, cell migration and invasion (Figure S5 and data not
Figure 1. Genomic loss of miR-204 in cancers. A, high resolution miRNA-CGH on selected pediatric renal tumors with (left) or without (right)
miR-204 deletions. Deletion of genomic loci containing the miRNA is indicated by dotted perpendicular lines. Red and green dots indicate position
and value of each probe reflecting copy number change, represented in triplicate on the CGH array. The grey trend line represents the average value
of the triplicate probe for each tumor. B, graphs obtained from meta-analysis of high-resolution CGH of ovarian cancers (n = 354; obtained from
TCGA) representing a subset of tumors with or without deletion. The deletion of genomic loci containing miR-204 is indicated by dotted
perpendicular lines. C and D, allelic PCR of miR-204 genomic locus in pediatric renal tumors (C) and ovarian cancers (D). The y-axis shows log2
transformed relative quantification values. Dotted lines show the loss of copy threshold. E–G, graphical representation of qRT-PCR analysis showing
levels of miR-204 in pediatric renal tumors (n = 38; E), in advanced stage ovarian cancers (n = 11; F) and, in breast cancers (n = 10; G), when compared
to normal matched control kidney (n = 38), normal ovarian tissues (n = 5) and normal matched breast tissues (n = 10).
doi:10.1371/journal.pone.0052397.g001
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shown). These results suggest that miR-204-mediated regulation of
BDNF and Ezrin is an important event in cancer cell growth,
migration and invasion.
Loss of miR-204 Activates AKT/mTOR Signaling and Rac1
Translocation in Cancer Cells
To determine the mechanism by which miR-204 may exhibit its
tumor growth and metastasis suppressor activity, we examined the
effect of miR-204 on AKT/mTOR signaling as both BDNF and
Ezrin have been shown to activate AKT pathway [27], and
selective activation of AKT by mTOR has been shown to regulate
cancer cell migration and invasion [28]. Interestingly, miR-204
overexpression resulted in reduced activity of AKT and mTOR
downstream targets 4E-BP1 and S6 (Figure 5A). 4E-BP1 is a
translation inhibitor that dissociates from eIF4E upon phosphor-
ylation to allow protein translation, and S6 is a ribosomal protein
whose phosphorylation facilitates assembly of the ribosome and
consequent translation of mRNA. To confirm our in vitro
findings, we analyzed expression of phospho-AKT (pAKT) and
phospho-S6 (pS6) in tumor xenograft overexpressing miR-204. As
shown in Figure S6, the levels of pAKT and pS6 were significantly
reduced, while total AKT and total S6 levels remain unchanged in
tumors overexpressing miR-204 when compared to control
transfectant tumors, as revealed by immunohistochemical analysis.
To further substantiate the notion that the AKT/mTOR pathway
is indeed an important target of miR-204, we co-transfected miR-
204 with the constitutively active AKT T308D/S473D mutant
and showed that constitutively active AKT rescued the negative
effects of miR-204 on downstream pS6 and phospho-4E-BP1
(p4E-BP1) levels (Figure 5, compare 5A and 5B). However, we
could not detect the rescue of negative effects mediated by miR-
204 on pAKT levels in cells co-transfected with constitutively
active AKT (Figure 5B). This is due to the mutation of Ser473 to
Asp473 in constitutively active AKT, and therefore the anti-
phospho-Ser473-AKT antibody used for the western blot analysis
only detected endogenous pAKT, which is reduced in level in the
presence of miR-204 (Figure 5A and 5B).
Figure 2. MiR-204 inhibits tumor growth and metastasis. A, miR-204 inhibits anchorage-independent growth. Nutrient consumption (left) and
graph (right) depict the number of colonies formed in soft agar wells by HEK-293 cells stably overexpressing either scramble or miR-204, further
transfected with miR-204 inhibitor. (*) P,0.05; (**) P,0.01. Results are the average of three independent experiments. B, miR-204 overexpression
inhibits tumor growth. Photograph shows representative features of tumor growth in RAG22/2, cc2/2 SCID mice injected (in the kidney capsule) with
HEK-293 cells stably overexpressing either scramble control or miR-204. Bar graph shows mean tumor volume for miR-204 (n = 9) and scramble (n = 9)
transfectants. (*) P,0.001. C, histological analysis of sections from tumor xenografts overexpressing either scramble (control) or miR-204. Images
shown in the right panel represent magnified view of boxed region indicated in the left panel. Tumor invasion in control transfectants is reflected by
the invasion of tumor into renal tissue. D, basement membrane matrix invasion assay of MDA-MB-231 cells transfected with 75 nM scrambled
sequence (control) or miR-204 mimic (miR-204) or miR-204 mimic transfected cells further transfected with miR-204 inhibitor (miR-204+inhibitor). Bar
graph shows the average number of invaded cells counted microscopically in five different fields per filter. (***) P,0.001.
doi:10.1371/journal.pone.0052397.g002
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AKT controls cell invasiveness by regulating multiple processes
that are involved in actin organization, cell-to-cell adhesion, and
cell motility [28,29,30]. To examine whether miR-204 may play a
direct role in this process, we assessed the effect of miR-204
Figure 3. Systemic delivery of miR-204 suppresses tumor metastasis. A, injection of miR-204 oligonucleotide into tail vein suppressed lung
metastasis. Live bioluminescence images of mice injected with miR-204 (n = 6) or miR-204 mutant (neg. control; n = 6) oligonucleotides using the
Xenogen In Vivo Imaging System (IVIS) (Xenogen). Images were taken after subcutaneously injecting 150 mg/kg D-luciferin substrate in PBS to
anesthetized mice. B, tumor metastasis volume was assessed starting from day 10 until animals were sacrificed at day 60. Using ROI analysis, tumor
light intensity was calculated in photon/s, which corresponds with the number of live cells in vivo. C, representative lung images showing GFP+ve foci
(red circle) in neg. control groups. D, representative lung sections showing metastatic foci in neg. control groups. E, no hepatotoxicity in miR-204
injected mice. Sections of liver from miR-204 injected mice show no signs of hepatotoxicity. The presence of multifocal periportal lymphocytes is not
unusual and is a common finding in young animals.
doi:10.1371/journal.pone.0052397.g003
Chromosomal Loss of miR-204
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overexpression on the activation of the small GTPase protein
Rac1, which functionally interacts with AKT/mTOR and is
reported to play a critical role in cell migration and actin
reorganization upon induction with BDNF [31] or epidermal
growth factor (EGF) [28]. Stimulation of MDA-MB-231 cells (and
SKOV3 or HEK-293 cells) with BDNF or EGF induced
membrane ruffling and caused Rac1 to be translocated to the
ruffling region (Figure 5C, Figure S7, and data not shown). In
contrast, the membrane ruffling and Rac1 translocation were not
observed in cells overexpressing miR-204 when induced with
BDNF or EGF (Figure 5C, Figure S7, and data not shown).
Evasion of apoptosis, which is critical for tumor growth and
progression [32] could be another mechanism central to onco-
genesis in cancers exhibiting loss of miR-204. Moreover, increased
AKT/mTOR activity has also been associated with decreased
apoptosis in cancers [33]. Indeed, miR-204 overexpression caused
Figure 4. MiR-204 regulates expression of BDNF in cancers. A–C, increased BDNF expression correlates strongly with lower miR-204
expression in multiple cancers. Graphical representation of qRT-PCR analysis showing the inverse correlation between miR-204 and BDNF in pediatric
renal tumors (n = 38; A), advanced stage ovarian cancers (n = 11; B) and breast cancers (n = 10; C), compared to normal matched control kidney
(n = 38), normal ovarian tissues (n = 5) and normal matched breast tissues (n = 10). D–H, BDNF is a bonafide target of miR-204. D, schematic of the
putative miR-204 binding sequence in the BDNF 39 UTR. E, HEK-293 cells were co-transfected with Renilla luciferase expression construct pRL-TK and
firefly luciferase constructs containing either pMIR-BDNF 39 UTR in the absence and presence of miR-204 mimic or pMIR-BDNF 39 UTR mutant. Firefly
luciferase activity of each sample was normalized to Renilla luciferase activity. Mean6SEM of three independent experiments (performed in duplicate
for each experiment). (**) P,0.01; (***) P,0.001. F, qRT-PCR analysis of miR-204 overexpressing cells and cells transfected with miR-204 inhibitors
using BDNF-specific primers. G, western blot analysis of HEK-293 cells transfected with miR-204 mimic using anti-BDNF antibody (1:1000). b-actin was
used as a loading control. Gel photographs are representative of three independent experiments. H, graphical representation of band intensities
quantified using the Total Labs TL100 1D gel analysis software (n = 3; Nonlinear). BDNF protein level for the control was set to 100.
doi:10.1371/journal.pone.0052397.g004
Chromosomal Loss of miR-204
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a significant increase in the levels of both activated caspase-3 and
poly ADP ribose polymerase (PARP), indicators of irreversible
damage to the integrity of the cell and genome, with a resultant
increase in apoptotic activity (Figure 5D and 5E). Taken together,
our findings suggest that loss of miR-204 promotes tumor cell
growth, migration and invasion by activating its target genes that
are known regulators of oncogenic signaling cascade.
Discussion
Many miRNAs associated with cancers are known to be
localized to genomic fragile sites [34]. However, surprisingly little
is known about the functional importance of regions with
chromosomal aberrations containing miRNAs. It is likely that
initial genetic screens (with lower comparative genomic hybrid-
ization resolution) aimed at discovering chromosomal abnormal-
ities overlooked changes in genomic regions containing miRNAs.
Because miRNAs influence several genes in one or more pathways
that regulate cell growth and apoptosis and contribute to tumor
formation when deregulated, a closer scrutiny of smaller genomic
regions encoding miRNAs will likely provide important insights
into the mechanism of tumorigenesis. Since most miRNAs are
proposed to be downregulated in cancers, we believe that
microdeletion of genetic regions containing specific miRNAs is a
more frequent event that plays an important role in the
development and progression of human cancers and merits
greater attention.
In this study we provide evidence that miR-204, which acts as a
potent tumor growth and metastasis suppressor, is somatically lost
in human cancers. We demonstrate that miR-204 regulates the
expression and function of pro-angiogenic protein BDNF and its
receptor TrkB in tumors. Our results show that loss of miR-204
Figure 5. MiR-204 inhibits tumor cell migration and invasion by altering AKT/mTOR/Rac1 signaling. A, miR-204 suppresses activation of
AKT and mTOR signaling. HEK-293 cells transfected with miR-204 were grown in serum-free conditions and subjected to western blot analysis using
anti-phospho-Ser473-AKT (1:1000), anti-total-AKT (1:1000), anti-phospho-Ser235/236-S6 (1:1000), anti-total-S6 (1:1000), anti-phospho-Thr37/46-4E-BP1
(1:1000) and anti-total-4E-BP1 (1:1000). b-actin (1:10,000) was used as a loading control. Gel photographs are representative of three independent
experiments. B, HEK-293 cells transfected with constitutively active AKT T308D/S473D mutant (CA-AKT) in the absence and presence of miR-204 were
grown in serum free condition and subjected to western blot analysis as descried in A. C, overexpression of miR-204 abolishes BDNF-induced
membrane ruffling and Rac1 translocation. HEK-293 cells transfected with miR-204 or miR-185 were grown in serum-free conditions and treated with
or without BDNF (100 ng/mL) for 10 min and stained with Rac1 antibody (red) and FITC-phalloidin (green). Arrows indicate membrane-ruffling
regions. D, miR-204 increases the sensitivity of HEK-293 cells to apoptosis as determined by Annexin V/PI staining using the FITC-Annexin V Apoptosis
Detection Kit. The percentage cell population shown is the mean6SEM of three independent experiments. E, western blot analysis of HEK-293 cells
transfected with miR-204 using anti-caspase-3 (1:500) antibody and anti-PARP (1:1000) show increased cleavage of caspase-3 and PARP. b-actin
(1:10,000) was used as a loading control. Gel photograph is representative of three independent experiments.
doi:10.1371/journal.pone.0052397.g005
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promotes BDNF (or EGF)-induced cancer cell migration and
invasion by activating AKT/mTOR pathway leading to Rac1
translocation and actin reorganization. Since AKT and Rac1
require each other for their activation [28,35], our findings suggest
that loss of miR-204 expression in human tumors may induce the
positive feedback loop between BDNF/AKT1/mTOR and Rac1
during cancer cell migration and invasion. Supporting this, both
mTOR complexes mTORC1 and mTORC2 have been reported
to regulate motility and metastasis of colorectal cancer via the
Rac1 signaling pathway [36], and Rac1 has been shown to
simultaneously regulate mTORC1 and mTORC2 [37]. Further-
more, BDNF, which activates GTP-bound Rac1 levels [38], has
been shown to be blocked by mTOR inhibitor rapamycin [39].
These studies, along with our results showing reduced levels of
pAKT/pS6K in cell lines and in tumors overexpressing miR-204,
strongly indicate that BDNF/AKT/mTOR/Rac1 signaling cas-
cade is one of the major targets of miR-204. Future studies aimed
at addressing the effect of miR-204 on mTORC1 and mTORC2
components such as Raptor/Sin1 will likely provide additional
insights. Similar to BDNF, our results show that miR-204 inhibits
EGF-induced activation of Rac1. This is significant as crosstalk
between EGFR and BDNF receptor TrkB has been shown to
induce cancer cell migration [40] and response to EGF is a key
step during cancer cell invasion and is directly linked with
metastasis [41]. These observations suggest that miR-204 may
have a broader role in altering growth factor-induced cancer cell
migration and invasion in general. In addition to cancer cell
migration and invasion, activation of BDNF/TrkB signaling may
also contribute to evasion of apoptosis in miR-204 depleted cells as
BDNF/TrkB overexpression has been linked with stabilization
and activation of AKT resulting in decreased apoptosis [42].
Consistent with this, our results show that miR-204 overexpression
results in reduced phosphorylation and activation of mTOR
downstream targets 4E-BP1 and S6 kinase.
Because miR-204 resides within the transient receptor potential cation
channel member 3 (TRPM3) gene, which is a member of transient
receptor potential channels family of proteins known to be
important for cellular calcium signaling and homeostasis, it will
be tempting to speculate that the phenotypes associated with the
genomic loss of chromosomal loci containing miR-204 may also be
contributed by the host gene TRPM3. Our results showing
suppression of tumor growth and metastasis following introduction
of miR-204 alone, and no change in the levels of TRPM3 gene in
miR-204 mimic or inhibitor overexpressing cancer cells (Figure
S8), clearly suggest that miR-204 associated tumor suppressor
phenotype is not mediated through TRPM3. However, we cannot
exclude the possibility that miR-204 and its host gene TRPM3 act
synergistically to regulate suppression of tumor growth as well as
tumor cell migration and invasion. Since a definite role for
TRPM3 in tumorigenesis has not been reported, a detailed study
examining TRPM3’s potential tumor suppressor role and its
synergistic effect with miR-204 (if any) will be subject of future
investigations.
Taken together, our findings suggest that genetic loci containing
specific miRNA may play a causal role in cancer growth and
metastasis by regulating key oncogenic pathway. The ability of
miR-204 to target BDNF/TrkB and Ezrin, which have significant
roles in normal cellular processes and are overexpressed in
aggressive cancers, indicates that miR-204 may control key
regulatory mechanisms, dysregulation of which can predispose
normal developmental/differentiation events to undergo transfor-
mation. Therefore, strategies aimed at using miR-204 as
therapeutic regimens will have the advantage of reversing
inappropriately activated steps in cancer cells to a more normal
state. The identification of miR-204 as a potent tumor suppressor
along with demonstration of its therapeutic potential and
negligible hepatotoxicity establish a strong rationale for developing
miR-204 as a viable therapeutic regimen to treat cancers.
Materials and Methods
Normal and Tumor Tissue Samples and Cell Lines
Cell lines representing pediatric renal tumors (HEK-293;
embryonal kidney cell line), ovarian (SKOV3), and breast
(MDA-MB-231) cancers used for experiments were obtained from
ATCC and cultured according to the protocols provided. Seventy-
six pediatric renal tumors and normal matched kidney were
acquired from the Children’s Oncology Group (Arcadia, CA).
Eleven advanced stage ovarian tumors and five normal ovarian
tissues were obtained from UT MD Anderson Cancer Center
(Houston, TX). Fifteen breast cancer tissues and normal matched
tissues were obtained from UT Health Science Center (San
Antonio, TX).
RNA and Protein Analyses
Total RNA was extracted from tumors and normal tissues, as
well as all cell lines, and was subjected to qRT-PCR analysis, as
described previously [43]. Western blot analysis was performed as
described previously [43]. Antibodies to b-actin (AC-74-A5316)
and a-tubulin (T6199) were purchased from Sigma Aldrich.
Antibody to BDNF was purchased from Santa Cruz, other
antibodies including caspase-8 (IC12-9746), caspase-3 (8G10-
9665), caspase-9 (9502), PARP (9542S), AKT (9272), phospho-
AKT (9271), S6 ribosomal protein (2217), and phospho-S6
ribosomal protein (5G10-2211S) were purchased from Cell
Signaling.
Genomic PCR Assay
Genomic DNA from pediatric renal tumors (n = 38), and
advanced stage (III and IV) ovarian cancers and matched normal
renal (n = 38) and ovarian (n = 4) tissues were isolated with the
DNeasy Genomic DNA Extraction Kit (Qiagen). For genomic
analysis of miR-204, the 22DDCt method was adapted using SYBR
Green-based quantitative PCR (qRT-PCR) as described [3].
Briefly, 25 ng of genomic DNA was used as template to amplify
the miR-204 locus. A representative control tissue sample was used
in every assay as a calibrator to which every sample was compared,
to obtain a relative quantitation (RQ) value. We used genomic
DNA from a normal male sample (1x) and a normal female sample
(2x) (Promega) to compare the levels of phosphoglycerate kinase 1
(PGK1) and five X-chromosome specific miRNAs – miR-424,
miR-503, miR-766, miR-222 and miR-221– to calibrate the
extent of loss in the various miRNA loci. RQ values for these
regions in male genomic DNA were assessed using the non-X-
chromosome TATA binding protein (TBP) gene as the reference.
Based on its ability to separate two distinct data populations, an
RQ value of 0.5 and below was considered as loss of at least one
copy of a genomic locus.
High-resolution miRNA Comparative Genomic
Hybridization Assay (CGH)
MiRNA CGH analysis was performed on the genomic DNA
isolated from pediatric renal tumor samples using an Agilent
custom-designed microarray as per the manufacturer’s protocol.
Custom arrays were designed based on the Agilent 26105K
Human Whole Genome Genomic Microarray using Agilent’s
eArray program (https://earray.chem.agilent.com/earray), with
additional probes that cover all miRNA regions (200 bp before,
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within and after of each miRNA from miRBase v13, with triplicate
probes to enhance reliability). Array CGH data analysis was
performed with Nexus Copy Number (BioDiscovery) for DNA
alteration quantification. Upon determination of samples with or
without copy number alteration at specific miRNA sites, all array
CGH data was loaded into MATLAB for a composite graphical
display. Array CGH showing position of the probes and
normalized copy numbers have been submitted to GEO/NCBI
data base (GSE28397).
Meta-analysis
Meta-analysis was performed on a public domain high density
CGH dataset on 354 ovarian cancers (obtained from The Cancer
Genome Atlas Project (TCGA, http://cancergenome.nih.gov))
and 35 breast cancers (GSE15130). Array CGH data for all
tumors imported into Nexus Copy Number. The threshold for
copy number loss was set to log2 20.5 (more stringent than the
default setting of log2 20.2). Meta-analysis for gene expression
analysis was performed on a public domain gene expression
dataset (GSE22820) from the GEO/NCBI. Differential expression
of TRPM3 (the locus containing miR-204) in breast cancer
samples was determined by first performing RMA/quantile
normalization and then comparing to normal adjacent tissues
within the same data set.
Gene Expression Analysis
Human gene expression microarray data were generated using
the Agilent Human Whole Genome 4644K array (Agilent
Technologies). Total RNA isolated from HEK-293 cells transfect-
ed with miR-204 was co-hybridized with RNA from HEK-293 cell
transfected with scrambled oligo (control) with dye-swap replicates,
following the manufacturer’s protocol. Relative gene expression
ratios were extracted with Agilent’s Feature Extraction software
(version 9.5.3.1, Agilent Technologies). Quantile normalization
was performed with the MATLAB Bioinformatics Toolbox
(R2009a, Mathworks). To determine differential expression of
genes, we applied the Student’s t-test to the normalized expression
data. Signature gene sets were selected based on an FDR-adjusted
P,0.05 (Benjamini-Hochberg) and a fold change .2. Differential
gene expression dataset has been deposited in GEO/NCBI data
base (GSE 28400).
Plasmid
For the pMIR-BDNF 39 UTR construct, the 39 UTR segment
of the BDNF gene was amplified and sub-cloned downstream of
the luciferase gene in the pMIR-REPORT vector (Ambion) at the
HindIII and SpeI sites. For the pSilencer-miR-204 construct,
,500 bp pri-miR-204 genomic sequence was amplified and
cloned into the BamHI and HindIII sites of the pSilencer 4.1 Puro
vector (Ambion). Constitutively active AKT T308D/S473D
mutant (Plasmid 14751) was purchased from Addgene Inc.
Cell Growth and Soft Agar Assay
Cell growth and soft agar colony formation assay using
pSilencer-miR-204 and pSilencer-scramble (control) stable cell
lines were performed as described previously [43].
Tumorigenicity Assays in SCID mice
Two million HEK-293 cells stably overexpressing either
pSilencer-miR-204 or pSilencer-scramble were injected into
the renal capsules of 9 RAG22/2, cc2/2 SCID male mice
(Taconic) and 9 control mice. Tumor volume was assessed 24 d
after transplantation, using the formula p/66(L6D6W), where
L is tumor length, D is depth and W is width. Six micrometer
paraffin embedded tumor sections were stained with hematox-
ylin and eosin. All experimental procedures involving animals
were performed according to institutional ethical guidelines.
Transwell Cell Migration and Basement Membrane Matrix
Invasion Assay
Transwell cell migration assays were performed as previously
described [43]. Invasion assays were performed with MDA-MB-
231 cells transfected with 75 nM miR-204 mimic or negative
control mimic, then further transfected for 48 h with 75 nM miR-
204-specific inhibitor or 25 ng of pBluescript KS+ control, as
described below. Forty-eight hours post-transfection, cells were
seeded onto the inserts of 24-well transwell plates precoated with
Matrigel (1 mg/mL) (BD Biosciences). Serum-containing media
and fibronectin (5 mg/mL) were added to the lower chamber as
chemoattractants. After 24 h incubation, cells on transwell inserts
were washed, fixed, and non-invading cells and EC matrix were
gently removed with a cotton swab. Invasive cells located on the
lower side of the chamber were stained with crystal violet (0.1%),
air dried and photographed as described [43].
Therapeutic Experiments
We injected 100,000 MDA-MB-231-GFP-luc cells (kindly
provided by Dr. Luzhe Sun, UTHSCSA, San Antonio, TX) into
the tail vein. Starting from 7 d after tumor cell injection we
injected miR-204 (n = 6) or miR-204 mutant (n = 6) oligos
complexed with RNALancerII in vivo delivery formulation (Bioo
Scientific) every 5 d for 30 d at a rate of 1 mg of oligo per kg of
body weight. All animals were sacrificed after the sixth injection.
Lungs were fixed and analyzed for metastatic foci. Lung images
were captured using fluorescence microscope (for GFP+ve and
luc+ve foci). We also harvested livers to assess metastasis and
hepatoxicity in miR-204 injected mice.
Apoptosis Assays
Annexin V/PI staining on HEK-293 or HeLa cells transfect-
ed with 75 nM miR-204 mimic or negative control mimic was
performed in triplicate wells using the FITC-Annexin V
Apoptosis Detection Kit (BD Pharmingen) as described previ-
ously [43].
Immunofluorescence
Cells were fixed with 4% paraformaldehyde and permeabi-
lized with 0.2% Triton X-100 for 15 min at room temperature
(RT), then washed with phosphate-buffered saline (PBS) and
blocked with 10% goat serum in PBS for 45 min at RT. Cells
were incubated with Rac1 mouse monoclonal antibody
(ab33186, Abcam) diluted in PBS for 2 h at RT. Cells were
washed three times before incubating for 1 h at RT with 1:200
Alexa Fluor 647 and Alexa Fluor 488 phalloidin-conjugated
secondary antibodies (A12379, Invitrogen, Molecular Probes).
After three washes, cells were mounted on glass slides in Aqua-
Poly/Mount medium containing DAPI (Polysciences). Photomi-
crographs were taken at 200x magnification on a Nikon Eclipse
TE2000-U microscope.
Statistical Analysis
All values and error bars in graphs are means 6 SEM;
respective n values are indicated in figure legends; P-values are
determined by two-tailed Student’s t-tests.
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Supporting Information
Figure S1 Copy number loss of chromosomal regions containing
miRNAs in tumors. A, list of miRNAs (obtained from high
resolution miRNA CGH (pediatric renal tumors and ovarian
cancers) and meta-analysis of public domain CGH database
(ovarian cancers and breast cancers) showing copy number loss in
all three tumors. B, graphs obtained from meta-analysis of high-
resolution CGH of breast cancers (n = 35; GSE 15130) represent a
subset of tumors with or without deletion.
(TIF)
Figure S2 Systemic delivery of miR-204 suppresses tumor
metastasis. A, live bioluminescence images of mice injected with
miR-204 or miR-204 mutant (control oligo injected) oligonucle-
otides using IVIS. Images were taken after subcutaneously
injecting 150 mg/kg D-luciferin substrate in PBS to anesthetized
mice. B, representative lung sections showing metastatic foci only
in neg. control group.
(TIF)
Figure S3 MiR-204 targets genes associated with tumorigenesis.
A, list of downregulated genes ($2-fold threshold) obtained from
microarray analyses on scramble or miR-204 overexpressing cells.
B, biological function analyses of downregulated genes ($2-fold
threshold) obtained from microarray analyses on cells overex-
pressing miR-204 using Ingenuity pathway analyses software.
MiR-204 target genes associated with biological functions and
canonical pathways in the Ingenuity Pathways Knowledge Base
were considered for the analysis. Fischer’s exact test was used to
calculate a p-value determining the probability that each biological
function and canonical pathway assigned to the candidate miRNA
target genes is due to chance alone. Biological functions and
canonical pathways with a P,0.05 were considered significant. C,
network analyses of downregulated genes ($2-fold threshold)
obtained from microarray analyses on HEK-293 cells overex-
pressing miR-204 using Ingenuity pathway analyses software.
Note that several of these network genes including BDNF and
Ezrin are known to be involved in tumorigenesis. Microarray
dataset is deposited in the GEO data base (GSE28397).
(TIF)
Figure S4 MiR-204 regulates expression of Ezrin in cancers.
Increased Ezrin expression correlates strongly with lower miR-204
expression in multiple cancers. Graphical representation of qRT-
PCR analysis showing the inverse correlation between miR-204
and Ezrin in pediatric renal tumors (n = 38; A), advanced stage
ovarian cancers (n = 11; B) and breast cancers (n = 10; C),
compared to normal matched control kidney (n = 38), normal
ovarian tissues (n = 5) and normal matched breast tissues (n = 10).
D–F, Ezrin is a bona fide target of miR-204. D, schematic of the
putative miR-204 binding sequence in the Ezrin 39 UTR (top).
HEK-293 cells were co-transfected with Renilla luciferase
expression construct pRL-TK and firefly luciferase constructs
containing pMIR-Ezrin 39 UTR in the absence and presence of
miR-204 mimic (bottom). Firefly luciferase activity of each sample
was normalized to Renilla luciferase activity. Mean6SEM of three
independent experiments (performed in duplicate for each
experiment). (**) P,0.01; (***) P,0.001. E, qRT-PCR analysis
of cells transfected with scramble or miR-204 mimic using Ezrin-
specific primers. F, western blot analysis of HEK-293 cells
transfected with miR-204 mimic using anti-Ezrin antibody
(1:2500). b-actin was used as a loading control. Gel photographs
are representative of three independent experiments. Values below
the gel were quantified using the Total Labs TL100 1D gel
analysis software. Ezrin protein level for the control was set to one.
(TIF)
Figure S5 BDNF rescues miR-204 associated phenotypes. A,
western blot analysis of ovarian cancer (SKOV3) and breast
cancer (MDA-MB-231) cells transfected with miR-204 mimic or
miR-204 inhibitors using anti-BDNF antibody (1:1000). b-actin
was used as a loading control. Gel photographs are representative
of three independent experiments. B and C, BDNF rescues miR-
204 mediated inhibition of cell migration and invasion. Migration
(B) and invasion (C) ability of MDA-MB-231 cells transfected with
either 10 nM negative control miRNA (control), miR-204 mimic
(miR-204) or miR-204 mimic and BDNF (miR-204+BDNF).
Photomicrographs represent three independent experiments (in
triplicate wells). Bar graph showing average number of migrated/
invaded cells counted microscopically (200x) in five different fields
per filter. (***) P,0.001; (**) P,0.01.
(TIF)
Figure S6 MiR-204 targets AKT/mTOR pathway. A and B,
immunohistochemical analysis on miR-204 overexpressing and
control transfectant tumor xenograft sections using anti-phospho-
Ser473-AKT (1:50; A, top), anti-total-AKT (1:50; A, bottom), anti-
phospho-Ser235/236-S6 (1:100; B, top) and anti-total-S6 (1:100; B,
bottom) antibodies.
(TIF)
Figure S7 Overexpression of miR-204 abolishes EGF-induced
membrane ruffling and Rac1 translocation. SKOV3 cells
transfected with miR-204 were grown in serum free condition
and treated with or without EGF (100 ng/ml) for 10 min and
stained with Rac1 antibody (red) and FITC-phalloidin (green).
Arrows indicate membrane-ruffling regions.
(TIF)
Figure S8 MiR-204 does not affect TRPM3 levels. QRT-PCR
analysis of HEK-293 cells transfected with scramble, miR-204
mimic or miR-204 inhibitor using TRPM3-specific primers.
(TIF)
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